The Problem We Solve

The need for safer, more effective medical solutions is critical. With the challenges of long-term NSAID and opioid use, the growing burden of cancer, and the devastating opioid epidemic, natural products offer a promising alternative. We are committed to developing innovative therapies that address these urgent needs, providing patients with better options for pain modulation, oncology, and beyond.

Cannabinoid science has lagged behind biotechnology due to compound stability and bioavailability issues. However, we are entering a new era, Medicine 3.0, where untapped natural compounds, improved treatments, and a focus on the human element are poised to revolutionize health and wellness.

PPARS, nuclear receptors that modulate genes related to metabolism and inflammation, are pivotal in drug development. Their involvement spans various therapeutic domains, including inflammatory diseases, metabolic disorders like diabetes and obesity, cardiovascular conditions, neurodegenerative diseases, and cancer. The increasing prevalence of metabolic disorders has spurred significant pharmaceutical interest in PPARS, leading to the development of novel products to fulfill unmet medical needs within the context of Medicine 3.0.

Building upon the advancements in pharmacogenomics and personalized medicine since the 1990s, our research focuses on leveraging PPAR nuclear receptors, powerful transcription factors that regulate gene expression and metabolism. We've discovered that acidic cannabinoids are potent activators of these receptors, and our innovative Intercalyx™ technology holds the potential to deliver these molecules directly to the cell nucleus, a feat yet to be empirically proven. Preliminary evidence suggests this approach could benefit a wide range of conditions, particularly acute inflammatory-mediated diseases and chronic pain.